Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1129 details
Primary information
ID10631
Therapeutic IDTh1129
Protein NameTesamorelin
Sequence>Th1129_Tesamorelin YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
Molecular Weight5005.76
Chemical FormulaC216H360N72O63S
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-life26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.
DescriptionStabilized synthetic peptide analogue of Growth Hormone Releasing Hormone (GHRH). It is used to treat excess abdominal fat in HIV-infected patients with lipodystrophy. It is a metabolic condition characterized by insulin resistance, fat redistribution and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Indication/DiseaseTesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
PharmacodynamicsTesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels.
Mechanism of ActionBy acting on the pituitary cells in the brain, tesamorelin stimulates production and release of the endogenous hormone (hGRF). Tesamorelin therapy predisposes the patient to glucose intolerance and can also increase the risk of type 2 diabetes, so the drug is contraindicated in pregnancy.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesNA
Patents NumberUS5861379
Date of Issue19-01-1999
Date of Expiry26-05-2020
Drug InteractionNA
TargetGrowth hormone-releasing hormone receptor
Brand NameEgrifta
CompanyTheratechnologies
Brand DescriptionTheratechnologies
Prescribed Forexcess abdominal fat in HIV-infected patients with lipodystrophy
Chemical NameNA
FormulationAfter reconstitution with the supplied diluent (Sterile Water for Injection, USP), a solution of EGRIFTA is clear and colorless. Each single-use vial of EGRIFTA contains 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and the following inactive ingredient: 100 mg mannitol, USP.
Physical Appearance EGRIFTA is a sterile, white to off-white, preservative-free lyophilized powder for subcutaneous injection
Route of AdministrationSubcutaneous
Recommended DosageThe recommended dose of EGRIFTA is 2 mg injected subcutaneously once a day.
ContraindicationDisruption of the Hypothalamic-pituitary Axis, Active Malignancy, Hypersensitivity and Pregnancy
Side Effectsrash, urticaria, arthralgia, extremity pain, peripheral edema, hyperglycemia, carpal tunnel syndrome, erythema, pruritis, pain, urticaria, irritation, swelling, hemorrhage
Useful Link 1Link
Useful Link 2NA
RemarksNA